The AMR Consortium of the Asia Africa Medical Innovation Consortium, for which AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) serves as the secretariat, discussed antimicrobial resistance (AMR) measures so far during the “Agenda4 – Making Unpredictable Communicable Disease Predictable by Economic Incentives and R&D” in the 10th NIKKEI FT Communicable Diseases Conference, organized by Nikkei INC. and co-sponsored by Financial Times. During the meeting, discussions were held on the progress of AMR measures to date, reflecting on the achievements of the AMR Consortium’s activities. The focus was on the future direction of sustainable research and development in the field of infectious diseases, including economic predictability. In the formulation of statements, input was provided by the AMR Consortium on the evaluation and improvement of the pull-type incentive system, and the establishment of a drug discovery ecosystem that contributes to infection control measures.

[Overview] (titles omitted) ※ Regarding the affiliation, please refer to the list of lecturers for the 10th NIKKEI FT Communicable Diseases Conference.

• Date: Tuesday, October 17, 2023
• Program: Agenda4 – Making Unpredictable Communicable Disease Predictable by Economic Incentives and R&D

NIKKEI FT Infectious Diseases Conference Chairs

Shigeru Omi (Japan Anti-Tuberculosis Association, Chairman, Representative, Board of Director / World Health Organization (WHO), Regional Office for Western Pacific)
Nahoko Shindo (Senior Advisor, WHO Health Emergencies Programme (WHE), World Health Organization)

Agenda4 – Making Unpredictable Communicable Disease Predictable by Economic Incentives and R&D

Moderator
Ryoji Noritake (CEO and Board Member, Health and Global Policy Institute (HGPI))

Discussion (Japanese syllabary order)
Hajime Inoue (Advisor; Health, Nutrition, and Population, The World Bank)
Norio Ohmagari (Director, National Center for Global Health and Medicine Hospital Disease Control and Prevention Center)
Kazumasa Oguro (Professor, Hosei University)
Michikazu Koshiba (Head, Center on Global Health Architecture, MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.)
Takuko Sawada (Director and Vice Chairperson of the Board, Shionogi & Co., Ltd.)
Hirokazu Shimoda (Director, Bio-Industry Division, Ministry of Economy, Trade and Industry (METI))
Manabu Sumi (Cabinet Councilor, Cabinet Agency for Infectious Disease Crises Management (CAICM), Cabinet Office, Government of Japan)
Nozomi Takeshita (Director, Office of Pandemic Preparedness and Response, Division of Infectious Disease Prevention and Control, Department of Infectious Disease Prevention and Control, Public Health Bureau, Ministry of Health, Labour and Welfare)
Yasunori Tawaragi (Environmental Management and Global Health Group Sustainability Promotion Department, DAIICHI SANKYO CO., LTD.)
Kazuhiro Tateda (Professor, Department of Microbiology and Infectious Diseases / Toho University School of Medicine)
Akihisa Harada (President & Representative Director, Pfizer Japan Inc.)
Eiji Hinoshita (Assistant Minister for Global Health and Welfare, Ministry of Health, Labour and Welfare of Japan)
Kyoko Matsumoto (Senior Associate, RDiscovery, KK)
Mitsuru Miyata (CEO, Miyata Institute of Technologies, K.K.)
Malin Grape (Sweden’s Ambassador on Antimicrobial Resistance)
Robert Matiru (Director, Programme Management, Unitaid)
John H. Rex (Chief Medical Officer, F2G Ltd. / Operating Partner, Advent Life Sciences)